Sign In
Buy OTLK
$0.98
-0.0634 (-6.10%)
At Close: Jul 31, 2026
Are Penny Stocks Worth It? 3 to Watch This Week
09:06am, Tuesday, 10'th Aug 2021
Trading penny stocks is more popular than ever; here's 3 you need to know about The post Are Penny Stocks Worth It? 3 to Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Informat
7 Penny Stocks That Have That ‘Get Rich' Potential
12:11pm, Monday, 09'th Aug 2021
If you want to travel on the speculative side of the market, these penny stocks might have the right stuff for you to strike it rich. The post 7 Penny Stocks That Have That ‘Get Rich' Potential appe
Best Biotech Penny Stocks For Your Small-Caps Watchlist Right Now
09:15am, Wednesday, 04'th Aug 2021
Biotech penny stocks are heating up right now; here's 3 to watch The post Best Biotech Penny Stocks For Your Small-Caps Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Infor
Why Outlook Therapeutics Stock Surged Today
05:34pm, Tuesday, 03'rd Aug 2021
Investors are excited about the potential of the drugmaker's experimental wet AMD treatment.
HC Wainwright Raises Price Target On Outlook Therapeutics After Wet AMD Trial Data
03:37pm, Tuesday, 03'rd Aug 2021
H.C. Wainwright raised the price target on Outlook Therapeutics Inc (NASDAQ:OTLK) to $6 from $5 and reiterated a Buy rating. The Company announced "exceptionally strong" data that showed Lytenava'
OTLK Stock Price Increases Over 30% Pre-Market: Why It Happened
06:53am, Tuesday, 03'rd Aug 2021
The stock price of Outlook Therapeutics Inc (NASDAQ: OTLK) increased by over 30% pre-market. This is why it happened.
Outlook Therapeutics Stock Surges Positive ONS-5010 Data In Wet AMD Patients
06:44am, Tuesday, 03'rd Aug 2021
Outlook Therapeutics Inc (NASDAQ: OTLK) stock is trading higher in premarket session in reaction to positive top-line results from Phase 3 NORSE TWO trial evaluating ONS-5010 / LYTENAVA (bevacizuma
ISELIN, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of
Hot Penny Stocks to Buy? 3 Stocks You Should Know About
02:45pm, Sunday, 02'nd May 2021
Penny stocks are ready for a new month; should you watch these 3? The post Hot Penny Stocks to Buy?
Outlook Therapeutics is bringing a treatment for retinal disease to the market at the right time
07:00am, Thursday, 29'th Apr 2021
There is something uniquely exciting about being the first company to bring a much-needed product to market. Outlook Therapeutics Inc (NASDAQ:OTLK) is hoping to become the first and only company to c
Why Bausch Health, Oncolytics Biotech, And More Are Moving Today
01:01pm, Wednesday, 17'th Feb 2021
iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for vaccine
Notable Insider Buys Of The Past Week: Harley-Davidson, Texas Instruments And More
01:27pm, Saturday, 06'th Feb 2021
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Some insiders have been taking advantage of secondary offerings recently.
Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update
09:05am, Wednesday, 23'rd Dec 2020
MONMOUTH JUNCTION, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved op
Outlook Therapeutics Announces Creation of Global Retina Advisory Council
08:05am, Thursday, 19'th Nov 2020
MONMOUTH JUNCTION, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved opht
Virtual KOL Roundtable Recap: Outlook Therapeutics and Firas Rahhal, MD, Discussed wet AMD Treatment Landscape and ONS-5010/LYTENAVA™
09:05am, Wednesday, 11'th Nov 2020
MONMOUTH JUNCTION, N.J., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved op
